Get started
MacroGenics, Inc.MacroGenics, Inc.MacroGenics, Inc.

MacroGenics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Options

MGNX chart


Full chart

MGNX upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪81.39 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.08 USD
Net income (FY)
‪−66.97 M‬ USD
Revenue (FY)
‪149.96 M‬ USD
Shares float
‪58.00 M‬
Beta (1Y)
1.84

Employees


Employees (FY)
341
Change (1Y)
+2 +0.59%
Revenue / Employee (1Y)
‪439.77 K‬ USD
Net income / Employee (1Y)
‪−196.38 K‬ USD

About MacroGenics, Inc.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Scott E. Koenig
Website
macrogenics.com
Headquarters
Rockville
Founded
2000
FIGI
BBG000BM2SF8
MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

MGNX news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as MGNX.

Frequently Asked Questions


The current price of MGNX is 1.27 USD — it has increased by 3.20% in the past 24 hours. Watch MacroGenics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange MacroGenics, Inc. stocks are traded under the ticker MGNX.
MGNX stock has risen by 17.27% compared to the previous week, the month change is a −44.16% fall, over the last year MacroGenics, Inc. has showed a −93.09% decrease.
We've gathered analysts' opinions on MacroGenics, Inc. future price: according to them, MGNX price has a max estimate of 8.00 USD and a min estimate of 2.00 USD. Watch MGNX chart and read a more detailed MacroGenics, Inc. stock forecast: see what analysts think of MacroGenics, Inc. and suggest that you do with its stocks.
MGNX reached its all-time high on Feb 3, 2014 with the price of 41.00 USD, and its all-time low was 0.99 USD and was reached on Apr 7, 2025. View more price dynamics on MGNX chart.
See other stocks reaching their highest and lowest prices.
MGNX stock is 10.83% volatile and has beta coefficient of 1.84. Track MacroGenics, Inc. stock price on the chart and check out the list of the most volatile stocks — is MacroGenics, Inc. there?
Today MacroGenics, Inc. has the market capitalization of ‪80.12 M‬, it has decreased by −9.84% over the last week.
Yes, you can track MacroGenics, Inc. financials in yearly and quarterly reports right on TradingView.
MacroGenics, Inc. is going to release the next earnings report on May 13, 2025. Keep track of upcoming events with our Earnings Calendar.
MGNX earnings for the last quarter are −0.24 USD per share, whereas the estimation was −0.28 USD resulting in a 13.90% surprise. The estimated earnings for the next quarter are −0.73 USD per share. See more details about MacroGenics, Inc. earnings.
MacroGenics, Inc. revenue for the last quarter amounts to ‪19.36 M‬ USD, despite the estimated figure of ‪35.71 M‬ USD. In the next quarter, revenue is expected to reach ‪9.59 M‬ USD.
MGNX net income for the last quarter is ‪−15.42 M‬ USD, while the quarter before that showed ‪56.31 M‬ USD of net income which accounts for −127.39% change. Track more MacroGenics, Inc. financial stats to get the full picture.
No, MGNX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 15, 2025, the company has 341 employees. See our rating of the largest employees — is MacroGenics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. MacroGenics, Inc. EBITDA is ‪−103.04 M‬ USD, and current EBITDA margin is −68.71%. See more stats in MacroGenics, Inc. financial statements.
Like other stocks, MGNX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade MacroGenics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So MacroGenics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating MacroGenics, Inc. stock shows the strong sell signal. See more of MacroGenics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.